Disease · MONDO_0016681
Comparisons in its trials22
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 22
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Randomized Arm 1: TMZ+RT + Placebo vs Randomized Arm 2: TMZ+RT + Bevacizumab: Incidence of Grade 3 and Higher Treatment-related Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 3.0 | 87 of 300 | 97 of 303 | 603 | NCT00884741 | Trial comparisons |
| Arm I (Bevacizumab and Temozolomide) vs Arm II (Bevacizumab and Irinotecan Hydrochloride): serious adverse events | 37 of 60 | 37 of 57 | 117 | NCT00433381 | Trial comparisons |
| Cohort 2: Bevacizumab+Placebo vs Cohort 2: Bevacizumab+AMG 386: Incidence of Grade 3+ Treatment-related Toxicity, Measured by CTCAE v. 4 (Cohort 2) | 21 of 57 | 20 of 57 | 114 | NCT01609790 | Trial comparisons |
| Phase I & Phase II-Arm B Pts: RT + TMZ + Vandetanib vs Phase II-Arm A Pts (Control Group): RT + TMZ: serious adverse events | 52 of 82 | 15 of 30 | 112 | NCT00441142 | Trial comparisons |
| Conventional Adjuvant TMZ vs Dose-dense Adjuvant TMZ: Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Interference Score at Cycle 4 | 7 of 51 | 13 of 40 | 91 | NCT00304031 | Trial comparisons |
| Conventional Adjuvant TMZ vs Dose-dense Adjuvant TMZ: Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Cycle 4 | 5 of 51 | 11 of 40 | 91 | NCT00304031 | Trial comparisons |
| Efficacy Group vs Safety Lead-in Group: serious adverse events | 32 of 59 | 7 of 15 | 74 | NCT00525525 | Trial comparisons |
| Stage 1: Dasatinib 200mg/Day vs Stage 1B: Dasatinib up to 400mg/Day: Number of Patients Achieving Objective Response (Partial or Complete Response) OR 6-month Progression-free Survival (6mPFS) | 1 of 21 | 2 of 29 | 50 | NCT00423735 | Trial comparisons |
| Stage 1: Dasatinib 200mg/Day vs Stage 1B: Dasatinib up to 400mg/Day: serious adverse events | 8 of 21 | 14 of 29 | 50 | NCT00423735 | Trial comparisons |
| Phase 1 Dose Escalation - Romidepsin vs Phase 2 Dose From Phase 1 - Romidepsin: serious adverse events | 0 of 8 | 0 of 40 | 48 | NCT00085540 | Trial comparisons |
Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure vs Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 9 of 9 | 21 of 26 | 35 | NCT01931098 | Trial comparisons |
| Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure vs Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure: deaths from any cause | 9 of 9 | 20 of 26 | 35 | NCT01931098 | Trial comparisons |
| Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure vs Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure: serious adverse events | 2 of 9 | 7 of 26 | 35 | NCT01931098 | Trial comparisons |
| Surgical Group vs Non-surgical Group: Number of Participants With Adverse Events as a Measure of Safety and Tolerability | 6 of 6 | 16 of 16 | 22 | NCT01227434 | Trial comparisons |
| Surgical Group vs Non-surgical Group: serious adverse events | 5 of 6 | 4 of 16 | 22 | NCT01227434 | Trial comparisons |
| Phase 1- Cohort 1 (250 mg Enzastaurin) vs Phase 1 Cohort 2 (500 mg Enzastaurin ): Phase 1 - Number of Participants With Adverse Events (AEs) | 0 of 6 | 1 of 6 | 12 | NCT00402116 | Trial comparisons |
| AXL1717, 400mg Initial Dose vs AXL1717, 300mg Initial Dose: Phase I Subjects - Imaging Evidence of Response. | 0 of 2 | 5 of 7 | 9 | NCT01721577 | Trial comparisons |
Participants With Primary Gliosarcoma vs Participants With Secondary Gliosarcoma: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 2 of 2 | 3 of 3 | 5 | NCT03641326 | Trial comparisons |
| Participants With Primary Gliosarcoma vs Participants With Secondary Gliosarcoma: Number of Participants With 6-month Progression Free Survival (PFS) | 0 of 2 | 0 of 3 | 5 | NCT03641326 | Trial comparisons |
| Participants With Primary Gliosarcoma vs Participants With Secondary Gliosarcoma: Number of Adverse Events Related to Drug | 0 of 2 | 0 of 3 | 5 | NCT03641326 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016681/comparisons